Alumis Closes $259 Million Series C
Cooley advised Alumis, a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize outcomes and transform the lives of patients with immune-mediated diseases, on its $259 million Series C.
Alto Neuroscience on its $147.9 Million IPO
Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering. Partners Div Gupta, Christina Roupas, Courtney Tygesson and Laurie Bauer led the Cooley team advising Alto.
CG Oncology on its $437 Million IPO
Cooley advised the underwriters of CG Oncology, a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, on the pricing of its upsized $437 million initial public offering. Partners Charlie Kim, Denny Won, Kristin VanderPas and David Peinsipp led […]
CARGO Therapeutics on its $281.3 Million IPO
Cooley advised the underwriters on CARGO Therapeutics’ $281.3 million initial public offering. Partners Denny Won, Charlie Kim, Kristin VanderPas and Dave Peinsipp led the Cooley team advising the underwriters.
Lexeo Therapeutics on its $100 Million IPO
Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering. Partners Eric Blanchard, Peter Byrne and Div Gupta led the Cooley team advising Lexeo.
Abivax on its $235.8 Million IPO
Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering. Partners Div Gupta, Marc Recht, Ryan Sansom and Denny Won led the Cooley team.
Instacart on its $660 Million IPO
Cooley represented Instacart, the leading grocery technology company in North America, on its $660 million initial public offering. Partners Jon Avina, Rachel Proffitt, Jonie Kondracki and Milson Yu led the Cooley team advising Instacart.
RayzeBio on its $357.6 Million IPO
Cooley advised RayzeBio, a targeted radiopharmaceutical company developing an innovative pipeline against solid tumor targets, on its upsized $357.6 million initial public offering. Partners Carlos Ramirez, Charlie Kim and Marya Postner led the Cooley team advising RayzeBio.
Neumora Therapeutics on its $250.1 Million IPO
Cooley advised the underwriters on the $250.1 million initial public offering of Neumora Therapeutics, a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. J.P. Morgan, BofA Securities, Stifel, Guggenheim Securities, RBC Capital […]
ImmuneOnco Biopharmaceuticals on its HK$319 Million IPO
Cooley advised ImmuneOnco Biopharmaceuticals, a clinical-stage biotechnology company dedicated to the development of immuno-oncology therapies, on its HK$319 million global initial public offering and listing on the Hong Kong Stock Exchange under stock code 1541. Partners Yiming Liu and Michael Yu led the Cooley team.